ALSO NOTED: FDA outlines tazarotene data demands; Elan repays $240M; FDA OKs BioMarin's Naglazyme; and much more...

> Irvine, California-based Allergan says that the FDA has outlined how it can improve oral tazarotene's risk-benefit profile. Allergan says it believes it can mount a pivotal trial to satisfy the agency's demands for new data. Release

> Despite problems with Tysabri, Ireland's Elan says it will retire more than $240 million in debt due in 2008. Release

> The FDA has approved BioMarin's Naglazyme for Maroteaux-Lamy syndrome, a rare disease in which a buildup of carbohydrates triggers a dysfunction of tissue and organs. Story

> The FDA has approved an expanded indication for Enbrel to physical function in patients with psoriatic arthritis. Release

> Bayer Greater China plans to rapidly expand its business in China with plans to invest $1.8 billion over six years. Story

> TransMolecular of Birmingham, Alabama, has begun a Phase II trial of 131I-TM-601 in adult patients with recurrent high-grade glioma. Release

> The board of India's Matrix Laboratories has approved a merger with Strides Arcolab. Release

> Codexis of Redwood City, California, has received its first milestone payment from Pfizer. Release

And Finally... Forbes examines the promising work of Canada's Vasogen in developing Celacade for fighting cardiac inflammation. Article

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.